MedTrace Logo

Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer

NCT02743923 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 203

Last updated 2021-12-21

No results posted yet for this study

Summary

The purpose of this study is to determine whether carboplatin-paclitaxel-bevacizumab results in a prolonged progression free survival compared to cisplatin-pemetrexed as first line treatment in patients with KRAS mutated non-small cell lung cancer.

Conditions

  • Carcinoma, Non-Small Cell Lung

Interventions

DRUG

carboplatin

AUC 6

DRUG

paclitaxel

200mg/m2

DRUG

Bevacizumab

15 mg/kg

DRUG

Pemetrexed

500 mg/m2

DRUG

cisplatin

75 mg/m2

Sponsors & Collaborators

  • Dutch Society of Physicians for Pulmonology and Tuberculosis

    collaborator OTHER

  • The Netherlands Cancer Institute

    lead OTHER

Principal Investigators

  • Anne-Marie C Dingemans, MD PhD · Dutch Society of Physicians for Pulmonology and Tuberculosis

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2021-09-19
Completion
2024-04-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02743923 on ClinicalTrials.gov